Paperbase

Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system

Bottai, Daria Frigui, Wafa Clark, Simon Rayner, Emma Zelmer, Andrea Andreu, Nuria de Jonge, Marien I. Bancroft, Gregory J. Williams, Ann Brodin, Priscille Brosch, Roland

Vaccine, 2015

https://doi.org/10.1016/j.vaccine.2015.03.083

simon clark

clark simon

ORCID: 0000-0003-1923-6120

Construction of a severely attenuated mutant of Mycobacterium tuberculosis for reducing risk to laboratory workers 10.1016/j.tube.2008.02.008

Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs 10.1111/j.1365-2567.2004.01809.x

Revaccination of Guinea pigs with the live attenuated Mycobacterium tuberculosis vaccine MTBVAC improves BCG's protection against tuberculosis 10.1093/infdis/jix030

Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs 10.1128/IAI.73.6.3814-3816.2005

Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens 10.1086/421468

Early lesions following aerosol infection of rhesus macaques (Macaca mulatta) with mycobacterium tuberculosis strain H37RV 10.1016/j.jcpa.2013.05.005

Establishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testing 10.1128/CVI.00079-10

An aerosol challenge model of tuberculosis in Mauritian cynomolgus macaques 10.1371/journal.pone.0171906

Intranasal bacille Calmette-Guérin (BCG) vaccine dosage needs balancing between protection and lung pathology 10.1111/j.1365-2249.2004.02648.x

Development of a diagnostic compatible BCG vaccine against Bovine tuberculosis 10.1038/s41598-019-54108-y

Label-free optical vibrational spectroscopy to detect the metabolic state of M. tuberculosis cells at the site of disease 10.1038/s41598-017-10234-z

Characterisation of a live Salmonella vaccine stably expressing the Mycobacterium tuberculosis Ag85B-ESAT6 fusion protein 10.1016/j.vaccine.2009.09.007

Protective efficacy of inhaled BCG vaccination against ultra-low dose aerosol M. Tuberculosis challenge in rhesus macaques 10.3390/pharmaceutics12050394

Non-replicating Mycobacterium tuberculosis elicits a reduced infectivity profile with corresponding modifications to the cell wall and extracellular matrix 10.1371/journal.pone.0087329

Protective efficacy of a lipid antigen vaccine in a guinea pig model of tuberculosis 10.1016/j.vaccine.2017.01.079

Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis 10.1016/j.tube.2004.09.009

Immunogenicity of orally-delivered lipid-formulated BCG vaccines and protection against Mycobacterium tuberculosis infection 10.1016/j.micinf.2008.09.004

Preclinical assessment of a new live attenuated Mycobacterium tuberculosis Beijing-based vaccine for tuberculosis 10.1016/j.vaccine.2019.11.085

Detecting phenotypically resistant Mycobacterium tuberculosis using wavelength modulated Raman spectroscopy 10.1007/978-1-4939-7638-6_4

Evaluation of the immunogenicity of Mycobacterium bovis BCG delivered by aerosol to the lungs of macaques 10.1128/CVI.00289-15

Ultra low dose aerosol challenge with Mycobacterium tuberculosis leads to divergent outcomes in rhesus and cynomolgus macaques 10.1016/j.tube.2015.10.004

Oral delivery of BCG Moreau Rio de Janeiro gives equivalent protection against tuberculosis but with reduced pathology compared to parenteral BCG Danish vaccination 10.1016/j.vaccine.2010.07.087

Improved protection in guinea pigs after vaccination with a recombinant BCG expressing MPT64 on its surface 10.1016/j.trivac.2015.03.003

The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs 10.1016/j.vaccine.2006.03.017

Pathogenic mycobacteria achieve cellular persistence by inhibiting the Niemann-Pick Type C disease cellular pathway 10.12688/wellcomeopenres.10036.1

Assessment of mycobacterium bovis deleted in p27-p55 virulence operon as candidate vaccine against tuberculosis in animal models 10.1155/2014/951978

Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials 10.1016/j.vaccine.2013.07.051

Selection of novel TB vaccine candidates and their evaluation as DNA vaccines against aerosol challenge 10.1016/j.vaccine.2006.05.025

Route of delivery to the airway influences the distribution of pulmonary disease but not the outcome of Mycobacterium tuberculosis infection in rhesus macaques 10.1016/j.tube.2015.11.004

Use of high frequency jet ventilation as a refinement for imaging macaques with respiratory disease 10.1177/0023677220913328

Oral vaccination of guinea pigs with a Mycobacterium bovis bacillus Calmette-Guérin vaccine in a lipid matrix protects against aerosol infection with virulent M. bovis 10.1128/IAI.00052-08

Re-formulation of selected DNA vaccine candidates and their evaluation as protein vaccines using a guinea pig aerosol infection model of tuberculosis 10.1016/j.tube.2006.01.014

Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system 10.1016/j.vaccine.2015.03.083

Animal models of tuberculosis: Guinea pigs 10.1101/cshperspect.a018572

Correlates between models of virulence for Mycobacterium tuberculosis among isolates of the Central Asian Lineage: A case for lysozyme resistance testing? 10.1128/IAI.03080-14

Determination of lesion volume by MRI and stereology in a macaque model of tuberculosis 10.1016/j.tube.2009.09.002

Assessment of different formulations of oral Mycobacterium bovis Bacille Calmette-Guérin (BCG) vaccine in rodent models for immunogenicity and protection against aerosol challenge with M. bovis 10.1016/j.vaccine.2008.08.028

Comparison of pellicle and shake flask-grown BCG strains by quality control assays and protection studies 10.1016/j.tube.2018.10.013

Induction of high levels of protective immunity in mice after vaccination using dendritic cells infected with auxotrophic mutants of Mycobacterium tuberculosis 10.1016/j.imlet.2005.10.011

Construction and characterization of the mycobacterium tuberculosis sigE fadD26 unmarked double mutant as a vaccine candidate 10.1128/IAI.00496-19

Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-γ producing T-cells 10.1016/j.vaccine.2008.10.034

Deletion of zmp1 improves Mycobacterium bovis BCG-mediated protection in a guinea pig model of tuberculosis 10.1016/j.vaccine.2015.01.058

The in vivo expressed Mycobacterium tuberculosis (IVE-TB) antigen Rv2034 induces CD4⁺ T-cells that protect against pulmonary infection in HLA-DR transgenic mice and guinea pigs 10.1016/j.vaccine.2014.05.005

Survival of Mycobacterium tuberculosis during experimental aerosolization and implications for aerosol challenge models 10.1111/j.1365-2672.2011.05069.x

Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases 10.1164/rccm.201110-1769OC

TBVAC2020: Advancing tuberculosis vaccines from discovery to clinical development 10.3389/fimmu.2017.01203

Intranasal IFNγ extends passive IgA antibody protection of mice against Mycobacterium tuberculosis lung infection 10.1111/j.1365-2249.2006.03012.x

Alternative BCG delivery strategies improve protection against Mycobacterium tuberculosis in non-human primates: Protection associated with mycobacterial antigen-specific CD4 effector memory T-cell populations 10.1016/j.tube.2016.09.004

Lipoarabinomannan mannose caps do not affect mycobacterial virulence or the induction of protective immunity in experimental animal models of infection and have minimal impact on in vitro inflammatory responses 10.1111/cmi.12065

Priscille Brodin

Brodin Priscille

ORCID: 0000-0003-0991-7344

Email: priscille.brodin@inserm.fr

How can nanoparticles contribute to antituberculosis therapy? 10.1016/j.drudis.2017.01.011

Host-directed therapies offer novel opportunities for the fight against tuberculosis 10.1016/j.drudis.2017.05.005

A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone 10.3390/toxins9070227

A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone 10.3390/toxins9070227 10.3390/toxins9070227.

Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections 10.2217/nnm-2016-0364

Cyclodextrin-based nanocarriers containing a synergic drug combination: a potential formulation for pulmonary administration of antitubercular drugs 10.1016/j.ijpharm.2017.05.030 10.1016/j.ijpharm.2017.05.030.

Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism 10.1007/s00401-016-1652-z

Host-directed therapies offer novel opportunities for the fight against tuberculosis 10.1016/j.drudis.2017.05.005 10.1016/j.drudis.2017.05.005.

Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria 10.1111/mmi.13535

Impact of pe_ pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis 10.3389/fcimb.2017.00137

LppM impact on the colonization of macrophages by Mycobacterium tuberculosis 10.1111/cmi.12619

Phenotypic assays for Mycobacterium tuberculosis infection 10.1002/cyto.a.23129 10.1002/cyto.a.23129.

Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420 10.1126/science.aag1006

A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters 10.1039/c5ob02630j

Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro 10.1007/s00705-016-2771-5

Mycobacterium tuberculosis LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization 10.1016/j.str.2016.07.009

Mycolactone The amazing analgesic mycobacterial toxin 10.1051/medsci/20163202007

STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection 10.1038/srep29297

2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1 10.1021/cb5007163

Cytosolic Access of Mycobacterium tuberculosis: Critical Impact of Phagosomal Acidification Control and Demonstration of Occurrence In Vivo 10.1371/journal.ppat.1004650

High content screening in chemical biology: overview and main challenges 10.1051/medsci/20153102016

High-Content Screening Technology Combined with a Human Granuloma Model as a New Approach To Evaluate the Activities of Drugs against Mycobacterium tuberculosis 10.1128/aac.03705-14

Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system 10.1016/j.vaccine.2015.03.083

Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro 10.3389/fmicb.2015.00438

Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action 10.1128/jvi.01473-15

Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays 10.1007/978-1-4939-2450-9_24

A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening 10.3791/51114

Ligand Efficiency Driven Design of New Inhibitors of Mycobacterium tuberculosis Transcriptional Repressor EthR Using Fragment Growing, Merging, and Linking Approaches 10.1021/jm500422b

Mycobacterial Toxin Induces Analgesia in Buruli Ulcer by Targeting the Angiotensin Pathways 10.1016/j.cell.2014.04.040

Potent antiviral activity of Solanum rantonnetii and the isolated compounds against hepatitis C virus in vitro 10.1016/j.jff.2014.09.022

A novel specific edge effect correction method for RNA interference screenings 10.1093/bioinformatics/btr648

Discovery of Novel N-Phenylphenoxyacetamide Derivatives as EthR Inhibitors and Ethionamide Boosters by Combining High-Throughput Screening and Synthesis 10.1021/jm3003779

Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors 10.1021/jm200825u

The Balance of Apoptotic and Necrotic Cell Death in Mycobacterium tuberculosis Infected Macrophages Is Not Dependent on Bacterial Virulence 10.1371/journal.pone.0047573

Analogous Mechanisms of Resistance to Benzothiazinones and Dinitrobenzamides in Mycobacterium smegmatis 10.1371/journal.pone.0026675

Ethionamide Boosters: Synthesis, Biological Activity, and Structure-Activity Relationships of a Series of 1,2,4-Oxadiazole EthR Inhibitors 10.1021/jm200076a

High-content screening in infectious diseases 10.1016/j.cbpa.2011.05.023

Functional characterization of the Mycobacterium tuberculosis serine/threonine kinase PknJ 10.1099/mic.0.038133-0

High Content Phenotypic Cell-Based Visual Screen Identifies Mycobacterium tuberculosis Acyltrehalose-Containing Glycolipids Involved in Phagosome Remodeling 10.1371/journal.ppat.1001100

High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery 10.4155/fmc.10.223

Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting 10.1016/j.biomaterials.2009.09.044

Automated High-Throughput siRNA Transfection in Raw 264.7 Macrophages: A Case Study for Optimization Procedure 10.1177/1087057108328762

Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis 10.1126/science.1171583

High Content Screening Identifies Decaprenyl-Phosphoribose 2 ' Epimerase as a Target for Intracellular Antimycobacterial Inhibitors 10.1371/journal.ppat.1000645

Systematic Genetic Nomenclature for Type VII Secretion Systems 10.1371/journal.ppat.1000507

Control of M-tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP 10.1371/journal.ppat.0040033

Aquatic insects and transmission of Mycobacterium ulcerans 10.1051/medsci/20072367572

ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity 10.1128/jb.00469-07

Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis 10.1371/journal.ppat.0030062

Protection against mycobacterium ulcerans lesion development by exposure to aquatic insect saliva 10.1371/journal.pmed.0040064

Support vector machines for automatic detection of tuberculosis bacteria in confocal microscopy images 10.1109/isbi.2007.356794

Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues 10.1016/j.bmc.2006.12.009

An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis 10.1128/iai.74.4.2128-2137.2006

Benzofuro 3,2-f 1 benzopyrans: A new class of antitubercular agents 10.1016/j.bmc.2006.03.033

Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence 10.1128/iai.74.1.88-98.2006

High frequency of CD4(+) T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection 10.1128/iai.02086-05

Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence 10.1128/jb.00631-06

Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis 10.1016/j.tube.2004.09.009

Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity 10.1074/jbc.M503515200

Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics 10.1099/mic.0.27799-0

Proteomic identification of M. tuberculosis protein kinase substrates: PknB recruits GarA, a FHA domain-containing protein, through activation loop-mediated interactions 10.1016/j.jmb.2005.05.049

Tuberculosis: from genome to vaccine 10.1586/14760584.4.4.541

Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RDI immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6 10.1128/iai.72.4.2170-2176.2004

Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens 10.1086/421468

ESAT-6 proteins: protective antigens and virulence factors? 10.1016/j.tim.2004.09.007

Macro-array and bioinformatic analyses reveal mycobacterial 'core' genes, variation in the ESAT-6 gene family and new phylogenetic markers for the Mycobacterium tuberculosis complex 10.1099/mic.0.26662-0

CD8(+)-T-cell responses of mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family 10.1128/iai.71.12.7173-7177.2003

Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis 10.1038/nm859

A new evolutionary scenario for the Mycobacterium tuberculosis complex 10.1073/pnas.052548299

Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant 10.1128/iai.70.10.5568-5578.2002

Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides 10.1021/bi015732y

Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti 10.1046/j.1365-2958.2002.03237.x

6-Oxocytidine containing oligonucleotides inhibit the HIV-1 integrase in vitro 10.1081/ncn-100002322

Determinants of Mg2+-dependent activities of recombinant human immunodeficiency virus type 1 integrase 10.1021/bi000398b

Inhibition of the human immunodeficiency virus type 1 DNA integration by modified oligonucleotides 10.1023/a:1026631910681

Branched oligonucleotide-intercalator conjugate forming a parallel stranded structure inhibits HIV-1 integrase 10.1016/s0014-5793(99)01350-2

Inhibition of HIV-1 integration by mono- & bi-functionalized triple helix forming oligonucleotides 10.1080/07328319908044831

Optimization of alternate-strand triple helix formation at the 5 '-TpA-3 ' and 5 '-ApT-3 ' junctions 10.1093/nar/27.15.3029

A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus 10.1074/jbc.272.25.16010

Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids 10.1073/pnas.1707840114

ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton 10.15252/embr.201744371

ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton 10.15252/embr.201744371 10.15252/embr.201744371.

Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles 10.1038/s41598-017-05453-3

Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis 10.1038/s41598-017-11843-4 10.1038/s41598-017-11843-4.

Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays 10.1021/acschembio.7b00091

Host-pathogen systems for early drug discovery against tuberculosis 10.1016/j.mib.2017.11.017 10.1016/j.mib.2017.11.017.

Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages 10.1016/j.chom.2017.07.020 10.1016/j.chom.2017.07.020. Epub 2017 Aug 31.

Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling 10.1016/j.celrep.2017.08.101 10.1016/j.celrep.2017.08.101.

Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids 10.1073/pnas.1707840114 10.1073/pnas.1707840114.

Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry 10.1128/jvi.01982-17

Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors 10.1016/j.celrep.2018.03.125

Oxadiazolone derivatives, new promising multi-target inhibitors against M. tuberculosis 10.1016/j.bioorg.2018.08.025

Proteomics of Mycobacterium infection: Moving towards a Better Understanding of Pathogen-Driven immunomodulation 10.3389/fimmu.2018.00086

Synergy between circular bacteriocin AS-48 and ethambutol against Mycobacterium tuberculosis 10.1128/aac.00359-18

The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase 10.1016/j.tube.2018.08.004

Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis 10.1038/s41598-017-11843-4

Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs 10.1016/j.ijpharm.2017.05.030

Host-pathogen systems for early drug discovery against tuberculosis 10.1016/j.mib.2017.11.017

Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages 10.1016/j.chom.2017.07.020

Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling 10.1016/j.celrep.2017.08.101

Phenotypic assays for Mycobacterium tuberculosis infection 10.1002/cyto.a.23129

A fast, fully automated cell segmentation algorithm for high-throughput and high-content screening 10.1002/cyto.a.20627

Compartmentalized Encapsulation of Two Antibiotics in Porous Nanoparticles: an Efficient Strategy to Treat Intracellular Infections 10.1002/ppsc.201800360

Spatiotemporal Changes of the Phagosomal Proteome in Dendritic Cells in Response to LPS Stimulation 10.1074/mcp.RA119.001316

Mycolactone as Analgesic: Subcutaneous Bioavailability Parameters 10.3389/fphar.2019.00378

Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis 10.1021/acsnano.8b07902

Mitochondrial Dynamics and Activity in Legionella-Infected Cells 10.1007/978-1-4939-9048-1_13

Heparin-Binding Hemagglutinin Adhesin (HBHA) Is Involved in Intracytosolic Lipid Inclusions Formation in Mycobacteria 10.3389/fmicb.2018.02258

Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication 10.1128/jvi.02009-18

A novel codrug made of the combination of ethionamide and its potentiating booster: synthesis, self-assembly into nanoparticles and antimycobacterial evaluation 10.1039/C9OB00680J

Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls 10.3390/toxins11090516

Paradoxical Roles of the MAL/Tirap Adaptor in Pathologies. 10.3389/fimmu.2020.569127

Fragment-Based Optimized EthR Inhibitors with in Vivo Ethionamide Boosting Activity. 10.1021/acsinfecdis.9b00277

Intracellular and in vivo evaluation of imidazo[2,1-b]thiazole-5-carboxamide anti-tuberculosis compounds. 10.1371/journal.pone.0227224

Preclinical assessment of a new live attenuated Mycobacterium tuberculosis Beijing-based vaccine for tuberculosis. 10.1016/j.vaccine.2019.11.085

IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection 10.1101/761551

Worms' Antimicrobial Peptides. 10.3390/md17090512

T(oo)bAd. 10.1038/s41589-019-0347-x

Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture. 10.1371/journal.pone.0198226

Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro. 10.3389/fmicb.2015.00488

Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. 10.1038/nm.3262

Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis. 10.1021/jm300377g

Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease. 10.1186/1753-6561-5-s1-p38

Automated HTS/HCS for antivirals using visual HIV full replication assays. 10.1186/1742-4690-6-s2-p82

Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system. 10.4049/jimmunol.174.6.3570

Cell microbiology interview 10.1111/cmi.13288

Pathogenomic analyses of Mycobacterium microti, an ESX-1-deleted member of the Mycobacterium tuberculosis complex causing disease in various hosts 10.1099/mgen.0.000505

Nathalie deboosere

deboosere Nathalie

ORCID: 0000-0002-2873-5485

ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton. 10.15252/embr.201744371

Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling. 10.1016/j.celrep.2017.08.101

A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone. 10.3390/toxins9070227

Phenotypic assays for Mycobacterium tuberculosis infection. 10.1002/cyto.a.23129

Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays. 10.1021/acschembio.7b00091

STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection. 10.1038/srep29297

LppM impact on the colonization of macrophages by Mycobacterium tuberculosis. 10.1111/cmi.12619

A microscopic phenotypic assay for the quantification of intracellular mycobacteria adapted for high-throughput/high-content screening. 10.3791/51114

Adhesion of human pathogenic enteric viruses and surrogate viruses to inert and vegetal food surfaces. 10.1016/j.fm.2012.04.007

Viral elution and concentration method for detection of influenza A viruses in mud by real-time RT-PCR. 10.1016/j.jviromet.2011.10.013

Comparison of chlorine and peroxyacetic-based disinfectant to inactivate Feline calicivirus, Murine norovirus and Hepatitis A virus on lettuce. 10.1016/j.ijfoodmicro.2011.08.011

Direct detection of highly pathogenic avian influenza A/H5N1 virus from mud specimens. 10.1016/j.jviromet.2011.06.002

Development and validation of a concentration method for the detection of influenza a viruses from large volumes of surface water. 10.1128/aem.02484-10

A predictive microbiology approach for thermal inactivation of Hepatitis A virus in acidified berries. 10.1016/j.fm.2010.05.018

Assessment of the removal and inactivation of influenza viruses H5N1 and H1N1 by drinking water treatment. 10.1016/j.watres.2010.01.013

Intra-laboratory validation of a concentration method adapted for the enumeration of infectious F-specific RNA coliphage, enterovirus, and hepatitis A virus from inoculated leaves of salad vegetables. 10.1016/j.ijfoodmicro.2005.11.007

Modelling effect of physical and chemical parameters on heat inactivation kinetics of hepatitis A virus in a fruit model system. 10.1016/j.ijfoodmicro.2003.10.015

Host-pathogen systems for early drug discovery against tuberculosis. 10.1016/j.mib.2017.11.017

Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids. 10.1073/pnas.1707840114

Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis. 10.1038/s41598-017-11843-4

Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages. 10.1016/j.chom.2017.07.020

Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles. 10.1038/s41598-017-05453-3

Host-directed therapies offer novel opportunities for the fight against tuberculosis. 10.1016/j.drudis.2017.05.005

Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs. 10.1016/j.ijpharm.2017.05.030

Impact of pe_pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis. 10.3389/fcimb.2017.00137

Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections. 10.2217/nnm-2016-0364

Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420. 10.1126/science.aag1006

How can nanoparticles contribute to antituberculosis therapy? 10.1016/j.drudis.2017.01.011

Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism. 10.1007/s00401-016-1652-z

Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria. 10.1111/mmi.13535

Mycobacterium tuberculosis LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization. 10.1016/j.str.2016.07.009

Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro. 10.1007/s00705-016-2771-5

[Mycolactone: the amazing analgesic mycobacterial toxin]. 10.1051/medsci/20163202007

A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters. 10.1039/c5ob02630j

Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action. 10.1128/jvi.01473-15

Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro. 10.3389/fmicb.2015.00488

Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system. 10.1016/j.vaccine.2015.03.083

Cytosolic access of Mycobacterium tuberculosis: critical impact of phagosomal acidification control and demonstration of occurrence in vivo. 10.1371/journal.ppat.1004650

[High content screening in chemical biology: overview and main challenges]. 10.1051/medsci/20153102016

Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays. 10.1007/978-1-4939-2450-9_24

2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1. 10.1021/cb5007163

High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against Mycobacterium tuberculosis. 10.1128/aac.03705-14

Mycobacterial toxin induces analgesia in buruli ulcer by targeting the angiotensin pathways. 10.1016/j.cell.2014.04.040

Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches. 10.1021/jm500422b

Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. 10.1038/nm.3262

The balance of apoptotic and necrotic cell death in Mycobacterium tuberculosis infected macrophages is not dependent on bacterial virulence. 10.1371/journal.pone.0047573

Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis. 10.1021/jm300377g

Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors. 10.1021/jm200825u

A novel specific edge effect correction method for RNA interference screenings. 10.1093/bioinformatics/btr648

Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis. 10.1371/journal.pone.0026675

High-content screening in infectious diseases. 10.1016/j.cbpa.2011.05.023

Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors. 10.1021/jm200076a

Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease. 10.1186/1753-6561-5-s1-p38

High content phenotypic cell-based visual screen identifies Mycobacterium tuberculosis acyltrehalose-containing glycolipids involved in phagosome remodeling. 10.1371/journal.ppat.1001100

High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery. 10.4155/fmc.10.223

Functional characterization of the Mycobacterium tuberculosis serine/threonine kinase PknJ. 10.1099/mic.0.038133-0

High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors. 10.1371/journal.ppat.1000645

Systematic genetic nomenclature for type VII secretion systems. 10.1371/journal.ppat.1000507

Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting. 10.1016/j.biomaterials.2009.09.044

Automated HTS/HCS for antivirals using visual HIV full replication assays. 10.1186/1742-4690-6-s2-p82

Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. 10.1126/science.1171583

Automated high-throughput siRNA transfection in raw 264.7 macrophages: a case study for optimization procedure. 10.1177/1087057108328762

Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP. 10.1371/journal.ppat.0040033

ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity. 10.1128/jb.00469-07

[Aquatic insects and transmission of Mycobacterium ulcerans]. 10.1051/medsci/20072367572

Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis. 10.1371/journal.ppat.0030062

Protection against Mycobacterium ulcerans lesion development by exposure to aquatic insect saliva. 10.1371/journal.pmed.0040064

Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues. 10.1016/j.bmc.2006.12.009

Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence. 10.1128/jb.00631-06

High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection. 10.1128/iai.02086-05

Benzofuro[3,2-f][1]benzopyrans: a new class of antitubercular agents. 10.1016/j.bmc.2006.03.033

An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis. 10.1128/iai.74.4.2128-2137.2006

Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence. 10.1128/iai.74.1.88-98.2006

Tuberculosis: from genome to vaccine. 10.1586/14760584.4.4.541

Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics. 10.1099/mic.0.27799-0

Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system. 10.4049/jimmunol.174.6.3570

Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. 10.1016/j.tube.2004.09.009

ESAT-6 proteins: protective antigens and virulence factors? 10.1016/j.tim.2004.09.007

Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens. 10.1086/421468

Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RD1 immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6. 10.1128/iai.72.4.2170-2176.2004

CD8+-T-cell responses of Mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family. 10.1128/iai.71.12.7173-7177.2003

Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. 10.1038/nm859

Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. 10.1046/j.1365-2958.2002.03237.x

Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant. 10.1128/iai.70.10.5568-5578.2002

Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides. 10.1021/bi015732y

IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection 10.1101/761551

Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology 10.1101/2021.06.30.450483

Nuria Andreu

Andreu Nuria

ORCID: 0000-0001-5768-6566

An integrated whole genome analysis of Mycobacterium tuberculosis reveals insights into relationship between its genome, transcriptome and methylome 10.1038/s41598-019-41692-2

Primary macrophages and J774 cells respond differently to infection with Mycobacterium tuberculosis 10.1038/srep42225

Triclosan-induced genes Rv1686c-Rv1687c and Rv3161c are not involved in triclosan resistance in Mycobacterium tuberculosis 10.1038/srep26221

Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system 10.1016/j.vaccine.2015.03.083

Deletion of zmp1 improves Mycobacterium bovis BCG-mediated protection in a guinea pig model of tuberculosis 10.1016/j.vaccine.2015.01.058

Noninvasive biophotonic imaging for studies of infectious disease 10.1111/j.1574-6976.2010.00252.x

Neutral-red reaction is related to virulence and cell wall methyl-branched lipids in Mycobacterium tuberculosis 10.1016/j.micinf.2005.06.011

Rapid in vivo assessment of drug efficacy against Mycobacterium tuberculosis using an improved firefly luciferase 10.1093/jac/dkt155

Setting up and monitoring an infection of Dictyostelium discoideum with mycobacteria 10.1007/978-1-62703-302-2_22

A new in vivo model to test anti-tuberculosis drugs using fluorescence imaging 10.1093/jac/dks161

Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases 10.1164/rccm.201110-1769OC

Rapid measurement of antituberculosis drug activity in vitro and in macrophages using bioluminescence 10.1093/jac/dkr472

Optimisation of bioluminescent reporters for use with mycobacteria 10.1371/journal.pone.0010777

Cell population heterogeneity in Mycobacterium tuberculosis H37Rv 10.1016/j.tube.2008.03.005

Neutral red staining of cells of a sulfolipid-deficient Mycobacterium tuberculosis pks2 mutant proves that sulfolipids are not responsible for this cytochemical reaction 10.1128/JCM.42.3.1379-1380.2004

Mycobacterium smegmatis displays the Mycobacterium tuberculosis virulence-related neutral red character when expressing the Rv0577 gene 10.1016/s0378-1097(04)00008-4

Simple and rapid differentiation of Mycobacterium tuberculosis H37Ra from M. tuberculosis clinical isolates through two cytochemical tests using neutral red and nile blue stains 10.1128/JCM.40.8.3021-3024.2002

Roland Brosch

Brosch Roland

ORCID: 0000-0003-2587-3863

Mycobacterium tuberculosis Meets the Cytosol: The Role of cGAS in Anti-mycobacterial Immunity. 10.1016/j.chom.2015.05.017

Insights on the emergence of Mycobacterium tuberculosis from the analysis of Mycobacterium kansasii 10.1093/gbe/evv035

Mycobacterial Pathogenomics and Evolution. 10.1128/microbiolspec.MGM2-0025-2013

Release of mycobacterial antigens 10.1111/imr.12251

Mycobacterium abscessus phospholipase C expression is induced during coculture within amoebae and enhances M. abscessus virulence in mice 10.1128/IAI.02032-14

Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system 10.1016/j.vaccine.2015.03.083

Genomic expression catalogue of a global collection of BCG vaccine strains show evidence for highly diverged metabolic and cell-wall adaptations 10.1038/srep15443

ESX/type VII secretion systems of mycobacteria: Insights into evolution, pathogenicity and protection 10.1016/j.tube.2015.02.019

Developing whole mycobacteria cell vaccines for tuberculosis: Workshop proceedings, Max Planck Institute for Infection Biology, Berlin, Germany, July 9, 2014 10.1016/j.vaccine.2015.03.056

Cytosolic Access of Mycobacterium tuberculosis: Critical Impact of Phagosomal Acidification Control and Demonstration of Occurrence In Vivo 10.1371/journal.ppat.1004650

Bovine tubercle bacilli: evolution associated with loss of transmission capacity in humans | Les bacilles de la tuberculose bovine - Une évolution aux dépens de la transmissibilité chez l'homme 10.1051/medsci/20153102003

Mycobacterium tuberculosis Exploits Asparagine to Assimilate Nitrogen and Resist Acid Stress during Infection 10.1371/journal.ppat.1003928

Mycobacterium tuberculosis evolutionary pathogenesis and its putative impact on drug development 10.2217/fmb.14.70

Evolutionary history of tuberculosis shaped by conserved mutations in the PhoPR virulence regulator 10.1073/pnas.1406693111

Bacillus calmette-guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy 10.1016/j.eururo.2014.02.061

A Specific polymorphism in Mycobacterium tuberculosis H37Rv causes differential ESAT-6 expression and identifies whiB6 as a novel ESX-1 component 10.1128/IAI.01824-14

A glimpse into the past and predictions for the future: The molecular evolution of the tuberculosis agent 10.1111/mmi.12720

TBCAP; Tuberculosis annotation project 10.1016/j.tube.2012.11.013

Identification and characterization of the genetic changes responsible for the characteristic smooth-to-rough morphotype alterations of clinically persistent Mycobacterium abscessus 10.1111/mmi.12387

Genomic analysis of smooth tubercle bacilli provides insights into ancestry and pathoadaptation of Mycobacterium tuberculosis 10.1038/ng.2517

ESX-1-induced apoptosis is involved in cell-to-cell spread of Mycobacterium tuberculosis 10.1111/cmi.12169

Characterization of Mycobacterium orygis 10.3201/eid1903.121005

The ESX-5 Associated eccB5-eccC5 Locus Is Essential for Mycobacterium tuberculosis Viability 10.1371/journal.pone.0052059

Strong immunogenicity and cross-reactivity of Mycobacterium tuberculosis ESX-5 type VII secretion-encoded PE-PPE proteins predicts vaccine potential 10.1016/j.chom.2012.03.003

Phagosomal rupture by Mycobacterium tuberculosis results in toxicity and host cell death 10.1371/journal.ppat.1002507

Multidrug-resistant tuberculosis in admitted patients at a tertiary referral hospital of Bangladesh 10.1371/journal.pone.0040545

Molecular epidemiology of tuberculosis in rural Matlab, Bangladesh 10.5588/ijtld.11.0426

ESX-1-mediated translocation to the cytosol controls virulence of mycobacteria 10.1111/j.1462-5822.2012.01799.x

ESX-1 dependent impairment of autophagic flux by Mycobacterium tuberculosis in human dendritic cells 10.4161/auto.20881

Disruption of the ESX-5 system of Mycobacterium tuberculosis causes loss of PPE protein secretion, reduction of cell wall integrity and strong attenuation 10.1111/j.1365-2958.2012.08001.x

Characterization of Mycobacterium orygis as M. tuberculosis complex subspecies 10.3201/eid1804.110888

Activation of the NLRP3 inflammasome by Mycobacterium tuberculosis is uncoupled from susceptibility to active tuberculosis 10.1002/eji.201141548

p62 and NDP52 proteins target intracytosolic Shigella and Listeria to different autophagy pathways 10.1074/jbc.M111.223610

Overexpression of proinflammatory TLR-2-signalling lipoproteins in hypervirulent mycobacterial variants 10.1111/j.1462-5822.2010.01565.x

ESAT-6 secretion-independent impact of ESX-1 genes espF and espG 1on virulence of Mycobacterium tuberculosis 10.1093/infdis/jiq089

Deciphering the role of IS6110 in a highly transmissible Mycobacterium tuberculosis Beijing strain, GC1237 10.1016/j.tube.2010.12.007

Synthesis, biological activity, and evaluation of the mode of action of novel antitubercular benzofurobenzopyrans substituted on A ring 10.1016/j.ejmech.2010.09.048

High content phenotypic cell-based visual screen identifies Mycobacterium tuberculosis acyltrehalose-containing glycolipids involved in phagosome remodeling 10.1371/journal.ppat.1001100

Entrapment of intracytosolic bacteria by septin cage-like structures 10.1016/j.chom.2010.10.009

Systematic genetic nomenclature for type VII secretion systems 10.1371/journal.ppat.1000507

Pathogenomics of mycobacteria 10.1159/000235772

Pathogenicity in the tubercle bacillus: Molecular and evolutionary determinants 10.1002/bies.200800191

Non mycobacterial virulence genes in the genome of the emerging pathogen Mycobacterium abscessus 10.1371/journal.pone.0005660

Myths and misconceptions: The origin and evolution of Mycobacterium tuberculosis 10.1038/nrmicro2165

Mycobacterial PE, PPE and ESX clusters: Novel insights into the secretion of these most unusual protein families 10.1111/j.1365-2958.2009.06784.x

High content screening identifies decaprenyl-phosphoribose 2′ epimerase as a target for intracellular antimycobacterial inhibitors 10.1371/journal.ppat.1000645

ESX/type VII secretion systems and their role in host-pathogen interaction 10.1016/j.mib.2008.11.003

Benzothiazinones Kill Mycobacterium tuberculosis by blocking Arabinan synthesis 10.1126/science.1171583

Insights from the complete genome sequence of Mycobacterium marinum on the evolution of Mycobacterium tuberculosis 10.1101/gr.075069.107

Functional analysis of a clonal deletion in an epidemic strain of Mycobacterium bovis reveals a role in lipid metabolism 10.1099/mic.0.2008/022269-0

Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP 10.1371/journal.ppat.0040033

BCG: Molecular history and new perspectives | Le BCG: Histoire moléculaire et nouvelles perspectives RMR-06-2008-25-00-01761-8425-101019-200806495

Genome plasticity of BCG and impact on vaccine efficacy 10.1073/pnas.0700869104

ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity 10.1128/JB.00469-07

Pathogenomics: Insights into Tuberculosis and Related Mycobacterial Diseases 10.1002/352760801X.ch10

Horizontal transfer of a virulence operon to the ancestor of Mycobacterium tuberculosis 10.1093/molbev/msj120

Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence 10.1128/IAI.74.1.88-98.2006

Contribution of mycobacterial genomics to the development of innovative strategies against tuberculosis | Apports de la génomique des mycobactéries a la définition de nouvelles stratégies thérapeutiques et vaccinales anti-tuberculeuses 10.1016/S1773-035X(06)80148-6

"A re-evaluation of M. prototuberculosis": Continuing the debate 10.1371/journal.ppat.0020095

Tuberculosis: From genome to vaccine 10.1586/14760584.4.4.541

Structure and mechanism of the alkyl hydroperoxidase AhpC, a key element of the Mycobacterium tuberculosis defense system against Oxidative Stress 10.1074/jbc.M503076200

Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: The contribution of endogenous mycolactone toxin 10.1111/j.1462-5822.2005.00546.x

Common evolutionary origin for the unstable virulence plasmid pMUM found in geographically diverse strains of Mycobacterium ulcerans 10.1128/JB.187.5.1668-1676.2005

Ancient origin and gene mosaicism of the progenitor of Mycobacterium tuberculosis 10.1371/journal.ppat.0010005

Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans 10.1073/pnas.0305877101

Genotypic Analysis of Mycobacterium tuberculosis in Bangladesh and Prevalence of the Beijing Strain 10.1128/JCM.42.2.674-682.2004

ESAT-6 proteins: Protective antigens and virulence factors? 10.1016/j.tim.2004.09.007

Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens 10.1086/421468

Cell Envelope Protein PPE68 Contributes to Mycobacterium tuberculosis RD1 Immunogenicity Independently of A 10-Kilodalton Culture Filtrate Protein and ESAT-6 10.1128/IAI.72.4.2170-2176.2004

Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis 10.1038/nm859

Is Mycobacterium africanum subtype II (Uganda I and Uganda II) a genetically well-defined subspecies of the Mycobacterium tuberculosis complex? [3] (multiple letters) 10.1128/JCM.41.3.1345-1348.2003

Royal society of tropical medicine and hygiene meeting at Manson house, London, 18 January 2001: Pathogen genomes and human health. Mycobacterial genomics 10.1016/S0035-9203(02)90222-1

Rapid and simple approach for identification of Mycobacterium tuberculosis complex isolates by PCR-based genomic deletion analysis 10.1128/JCM.40.7.2339-2345.2002

Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti 10.1046/j.1365-2958.2002.03237.x

Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant 10.1128/IAI.70.10.5568-5578.2002

A new evolutionary scenario for the Mycobacterium tuberculosis complex 10.1073/pnas.052548299

The evolution of mycobacterial pathogenicity: Clues from comparative genomics 10.1016/S0966-842X(01)02131-X

Genomics of Mycobacterium bovis 10.1054/tube.2000.0269

Tools for the population genomics of the tubercle bacilli 10.1101/gr.169200

Comparative genomics of the leprosy and tubercle bacilli 10.1016/S0923-2508(00)00117-0

Identification of variable regions in the genomes of tubercle bacilli using bacterial artificial chromosome arrays 10.1046/j.1365-2958.1999.01383.x

Analysis of the proteome of Mycobacterium tuberculosis in silico 10.1054/tuld.1999.0220

The high-pathogenicity island of Yersinia pseudotuberculosis can be inserted into any of the three chromosomal asn tRNA genes 10.1046/j.1365-2958.1998.01124.x

Deciphering the biology of mycobacterium tuberculosis from the complete genome sequence 10.1038/31159

Genomic fingerprinting of 80 strains from the WHO multicenter international typing study of Listeria monocytogenes via pulsed-field gel electrophoresis (PFGE) 10.1016/S0168-1605(96)01147-6

Characterization of Listeria strains isolated from soft cheese 10.1016/0168-1605(93)90220-B

Listeriosis outbreak in France in 1992. Microbial data | Epidémie de listériose en France en 1992 aspects microbiologiques 10.1016/S0399-077X(05)81214-4

Use of pulsed field gel electrophoresis to compare large DNA-restriction fragments of Listeria monocytogenes strains belonging to serogroups 1/2 and 3 10.1016/0168-1605(91)90121-5

Subtyping of Listeria monocytogenes serovar 4b by use of low-frequency-cleavage restriction endonucleases and pulsed-field gel electrophoresis 10.1016/0923-2508(91)90080-T

Impact of Mycobacterium tuberculosis RD1-locus on human primary dendritic cell immune functions 10.1038/srep17078

Revisiting the role of phospholipases C in virulence and the lifecycle of Mycobacterium tuberculosis 10.1038/srep16918

Drug-resistant tuberculosis in the European Union: opportunities and challenges for control. 10.1016/j.tube.2010.03.008

The BCG Strain Pool: Diversity Matters. 10.1038/mt.2016.18

Genome-wide mosaicism within Mycobacterium abscessus: evolutionary and epidemiological implications. 10.1186/s12864-016-2448-1

Perspectives on mycobacterial vacuole-to-cytosol translocation: the importance of cytosolic access. 10.1111/cmi.12622

Key experimental evidence of chromosomal DNA transfer among selected tuberculosis-causing mycobacteria 10.1073/pnas.1604921113

Comparative Genomics and Evolution of Mycobacterium bovis BCG 10.1128/9781555817657.ch10

The Mycobacteria: a Postgenomic View 10.1128/9781555815530.ch3

Genomics ofMycobacterium Tuberculosis and Mycobacterium Leprae 10.1002/9781444311433.ch5

Genomics of the Mycobacterium tuberculosis complex and Mycobacterium leprae 10.1002/047001153x.g205204

ESX secretion systems: mycobacterial evolution to counter host immunity 10.1038/nrmicro.2016.131

Resistance to thiacetazone derivatives active against Mycobacterium abscessus involves mutations in the MmpL5 transcriptional repressor MAB_4384 10.1128/aac.02509-16

ESX-1 and phthiocerol dimycocerosates of Mycobacterium tuberculosis act in concert to cause phagosomal rupture and host cell apoptosis. 10.1111/cmi.12726

Colonization with Helicobacter is concomitant with modified gut microbiota and drastic failure of the immune control of Mycobacterium tuberculosis 10.1038/mi.2016.140

Recombinant BCG Expressing ESX-1 of Mycobacterium marinum Combines Low Virulence with Cytosolic Immune Signaling and Improved TB Protection 10.1016/j.celrep.2017.02.057

PknG senses amino acid availability to control metabolism and virulence of Mycobacterium tuberculosis 10.1371/journal.ppat.1006399

Predicting susceptibility to tuberculosis based on gene expression profiling in dendritic cells 10.1038/s41598-017-05878-w

Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling 10.1016/j.celrep.2017.08.101

Evolution of virulence in the Mycobacterium tuberculosis complex 10.1016/j.mib.2017.11.021

The Macrophage: A Disputed Fortress in the Battle against Mycobacterium tuberculosis 10.3389/fmicb.2017.02284

Mutations in ppe38 block PE_PGRS secretion and increase virulence of Mycobacterium tuberculosis 10.1038/s41564-017-0090-6

Discovery of the type VII ESX-1 secretion needle? 10.1111/mmi.13579

Identification of genes required forMycobacterium abscessusgrowth in vivo with a prominent role of the ESX-4 locus 10.1073/pnas.1713195115

Mycobacterial ESX-1 secretion system mediates host cell lysis through bacterium contact-dependent gross membrane disruptions 10.1073/pnas.1620133114

Horizontal acquisition of a hypoxia-responsive molybdenum cofactor biosynthesis pathway contributed to Mycobacterium tuberculosis pathoadaptation 10.1371/journal.ppat.1006752

The Biology and Epidemiology of Mycobacterium canettii 10.1007/978-3-319-64371-7_2

Targeting Type VII/ESX Secretion Systems for Development of Novel Antimycobacterial Drugs 10.2174/1381612819666131118170717

Taxonomic Diversity of Pseudomonads Revealed by Computer-interpretation of Ribotyping Data 10.1016/s0723-2020(96)80026-9

Comparative genomics of the mycobacteria 10.1016/s1438-4221(00)80083-1

Single Cell Measurements of Vacuolar Rupture Caused by Intracellular Pathogens 10.3791/50116

Type VII Secretion Systems in Gram-Positive Bacteria 10.1007/82_2015_5015

Genomic characterization of Mycobacterium tuberculosis lineage 7 and a proposed name: ‘Aethiops vetus’ 10.1099/mgen.0.000063

Leprosy in red squirrels 10.1126/science.aal0145

CD4+ T Cells Recognizing PE/PPE Antigens Directly or via Cross Reactivity Are Protective against Pulmonary Mycobacterium tuberculosis Infection 10.1371/journal.ppat.1005770

pks5-recombination-mediated surface remodelling in Mycobacterium tuberculosis emergence 10.1038/nmicrobiol.2015.19

A unique PE_PGRS protein inhibiting host cell cytosolic defenses and sustaining full virulence ofMycobacterium marinumin multiple hosts 10.1111/cmi.12606

The PE and PPE Protein Families of Mycobacterium tuberculosis 10.1002/9783527611614.ch7

Influence of ESAT-6 Secretion System 1 (RD1) of Mycobacterium tuberculosis on the Interaction between Mycobacteria and the Host Immune System 10.4049/jimmunol.174.6.3570

Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors 10.1016/j.celrep.2018.03.125

ESAT-6–dependent cytosolic pattern recognition drives noncognate tuberculosis control in vivo 10.1172/jci84978

Cutting-edge science and the future of tuberculosis control 10.2471/blt.06.035386

ESAT-6 and the Mycobacterial ESX Secretion Systems 10.1128/9781555815783.ch13

RD5-mediated lack of PE_PGRS and PPE-MPTR export in BCG vaccine strains results in strong reduction of antigenic repertoire but little impact on protection 10.1371/journal.ppat.1007139

Unexpected genomic and phenotypic diversity of Mycobacterium africanum Lineage 5 affects drug resistance, protein secretion and immunogenicity 10.1093/gbe/evy145

New substrates and interactors of the mycobacterial Serine/Threonine protein kinase PknG identified by a tailored interactomic approach 10.1016/j.jprot.2018.09.013

Update on the virulence factors of the obligate pathogen Mycobacterium tuberculosis and related tuberculosis-causing mycobacteria 10.1016/j.meegid.2018.12.013

Shared Pathogenomic Patterns Characterize a New Phylotype, Revealing Transition toward Host-Adaptation Long before Speciation of Mycobacterium tuberculosis 10.1093/gbe/evz162

Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis. 10.1021/acsnano.8b07902

Mycobacterial virulence: impact on immunogenicity and vaccine research 10.12688/f1000research.20572.1

TbD1 deletion as a driver of the evolutionary success of modern epidemic Mycobacterium tuberculosis lineages 10.1038/s41467-020-14508-5

Discovery of a novel dehydratase of the fatty acid synthase type II critical for ketomycolic acid biosynthesis and virulence of Mycobacterium tuberculosis 10.1038/s41598-020-58967-8

ESX/Type VII Secretion Systems—An Important Way Out for Mycobacterial Proteins 10.1128/microbiolspec.psib-0029-2019

ESX-4, un système de sécrétion mycobactérien ancestral, essentiel pour la croissance de Mycobacterium abscessus dans les phagocytes environnementaux et humains 10.1051/medsci/2018196

Mycobacterium abscessus virulence traits unraveled by transcriptomic profiling in amoeba and macrophages 10.1371/journal.ppat.1008069

A systematic approach to simultaneously evaluate safety, immunogenicity, and efficacy of novel tuberculosis vaccination strategies 10.1126/sciadv.aaz1767

Live attenuated TB vaccines representing the three modern Mycobacterium tuberculosis lineages reveal that the Euro–American genetic background confers optimal vaccine potential 10.1016/j.ebiom.2020.102761

Mucosal delivery of ESX-1–expressing BCG strains provides superior immunity against tuberculosis in murine type 2 diabetes 10.1073/pnas.2003235117

Le BCG : histoire moléculaire et nouvelles perspectives 10.1016/s0761-8425(08)56032-3

Breaching the phagosome, the case of the tuberculosis agent 10.1111/cmi.13344

Pathogenomic analyses of Mycobacterium microti, an ESX-1-deleted member of the Mycobacterium tuberculosis complex causing disease in various hosts 10.1099/mgen.0.000505

The antibiotic bedaquiline activates host macrophage innate immune resistance to bacterial infection 10.7554/elife.55692

IL-1R1-Dependent Signals Improve Control of Cytosolic Virulent Mycobacteria In Vivo 10.1128/mSphere.00153-21

ESX-1-Independent Horizontal Gene Transfer by Mycobacterium tuberculosis Complex Strains 10.1128/mBio.00965-21

Evolution of Mycobacterium tuberculosis : New Insights into Pathogenicity and Drug Resistance 10.1128/microbiolspec.tbtb2-0020-2016

Phthiocerol Dimycocerosates From Mycobacterium tuberculosis Increase the Membrane Activity of Bacterial Effectors and Host Receptors 10.3389/fcimb.2020.00420

Parallel in vivo experimental evolution reveals that increased stress resistance was key for the emergence of persistent tuberculosis bacilli 10.1038/s41564-021-00938-4

Wafa FRIGUI

FRIGUI Wafa

ORCID: 0000-0001-5172-7961

Mycobacterial virulence: impact on immunogenicity and vaccine research [version 1; peer review: 4 approved] 10.12688/f1000research.20572.1

Recombinant BCG Expressing ESX-1 of Mycobacterium marinum Combines Low Virulence with Cytosolic Immune Signaling and Improved TB Protection. 10.1016/j.celrep.2017.02.057

PknG senses amino acid availability to control metabolism and virulence of Mycobacterium tuberculosis. 10.1371/journal.ppat.1006399

Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors. 10.1016/j.celrep.2018.03.125

pks5-recombination-mediated surface remodelling in Mycobacterium tuberculosis emergence. 10.1038/nmicrobiol.2015.19

The changes in mycolic acid structures caused by hadC mutation have a dramatic effect on the virulence of Mycobacterium tuberculosis. 10.1111/mmi.13266

Revisiting the role of phospholipases C in virulence and the lifecycle of Mycobacterium tuberculosis. 10.1038/srep16918

CD4+ T Cells Recognizing PE/PPE Antigens Directly or via Cross Reactivity Are Protective against Pulmonary Mycobacterium tuberculosis Infection. 10.1371/journal.ppat.1005770

ESX/type VII secretion systems of mycobacteria: Insights into evolution, pathogenicity and protection. 10.1016/j.tube.2015.02.019

Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system. 10.1016/j.vaccine.2015.03.083

A specific polymorphism in Mycobacterium tuberculosis H37Rv causes differential ESAT-6 expression and identifies WhiB6 as a novel ESX-1 component. 10.1128/IAI.01824-14

Genomic analysis of smooth tubercle bacilli provides insights into ancestry and pathoadaptation of Mycobacterium tuberculosis. 10.1038/ng.2517

Early trafficking events of Mycobacterium ulcerans within Naucoris cimicoides. 10.1111/j.1462-5822.2006.00790.x

Disruption of the ESX-5 system of Mycobacterium tuberculosis causes loss of PPE protein secretion, reduction of cell wall integrity and strong attenuation. 10.1111/j.1365-2958.2012.08001.x

ESAT-6 secretion-independent impact of ESX-1 genes espF and espG1 on virulence of Mycobacterium tuberculosis. 10.1093/infdis/jiq089

Validation of the reshaped shared epitope HLA-DRB1 classification in rheumatoid arthritis. 10.1186/ar1949

Genome plasticity of BCG and impact on vaccine efficacy. 10.1073/pnas.0700869104

Reductive evolution and niche adaptation inferred from the genome of Mycobacterium ulcerans, the causative agent of Buruli ulcer. 10.1101/gr.5942807

Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. 10.1073/pnas.0305877101

Common evolutionary origin for the unstable virulence plasmid pMUM found in geographically diverse strains of Mycobacterium ulcerans. 10.1128/JB.187.5.1668-1676.2005

Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP. 10.1371/journal.ppat.0040033

RD5-mediated lack of PE_PGRS and PPE-MPTR export in BCG vaccine strains results in strong reduction of antigenic repertoire but little impact on protection 10.1371/journal.ppat.1007139

Discovery of a novel dehydratase of the fatty acid synthase type II critical for ketomycolic acid biosynthesis and virulence of Mycobacterium tuberculosis 10.1038/s41598-020-58967-8